Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Biotene Dry Mouth Oral Rinse is a commercially available over-the-counter oral rinse formulated as a saliva substitute to relieve the symptoms of dry mouth (xerostomia). It is a non-biologic, small molecule topical formulation containing a combination of moisturizers and humectants, including glycerin, xylitol, sorbitol, and propylene glycol, and is free of alcohol, sugar, and sodium lauryl sulfate (SLS). The rinse acts by retaining water and lubricating the oral mucosal tissue, providing up to 4 hours of symptomatic relief per use. It is being evaluated in clinical trials, such as the 'BIG DRY' perioperative trial in New Zealand led by Dr. Doug Campbell, to assess its efficacy in reducing preoperative dry mouth in elective adult surgical patients compared to a water mouth rinse.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Biotene Dry Mouth Oral Rinse.